Inhibition of HIV-1 replication by daunorubicin.
Members of the anthracycline family of drugs such as daunorubicin (DNR) are currently being employed in cancer therapy, treatment of Kaposi's sarcoma and lymphomas in HIV-1 infected patients. These drugs may have an anti-viral activity against HIV-1. Experiments conducted on U937 (a promonocytic cell line), peripheral blood monocytes (without T cells) and infected with HIV-1 showed anti-viral activity at nanogram/ml concentrations, without affecting cell proliferation and cell viability. Treatment of Hut 78 cells (a T cell line) with DNR was not as effective in inhibiting HIV-1 replication when compared to the anti-HIV activity in cells of the monocyte lineage.